Indication
generalized lipodystrophy
3 clinical trials
4 products
1 drug
Product
PlaceboClinical trial
A Randomized, Double-Blind, Placebo-Controlled Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized LipodystrophyStatus: Active (not recruiting), Estimated PCD: 2022-01-05
Product
REGN4461Product
MetreleptinClinical trial
A 36-Month, Multicenter, Open Label Phase 4 Study to Evaluate the Immunogenicity of Daily SC Metreleptin Treatment in Patients With Generalized LipodystrophyStatus: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
Double-Blind, Placebo-Controlled Trial of Leptin Replacement Therapy in Patients With LipodystrophyStatus: Completed, Estimated PCD: 2014-11-01
Product
LeptinDrug
Varlilumab